OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study

Ocugen completed enrollment early in the GARDian3 trial for OCU410ST, accelerating the development timeline for its gene therapy targeting Stargardt disease, a condition with no approved treatments. The company expects data readouts in Q3, creating a near-term clinical catalyst; positive upside exists but outcome is binary and dependent on trial safety/efficacy data.

Analysis

Ocugen completed enrollment early in the GARDian3 trial for OCU410ST, accelerating the development timeline for its gene therapy targeting Stargardt disease, a condition with no approved treatments. The company expects data readouts in Q3, creating a near-term clinical catalyst; positive upside exists but outcome is binary and dependent on trial safety/efficacy data.